The January 2025 Head Start webinar explored the UNITE study (n=353), a multi-centre, 12-week double-blind, placebo-controlled, parallel-group, randomised clinical trial followed by an open-label extension, to evaluate the efficacy and safety of fremanezumab in patients with migraine and major depressive disorder (MDD).1 This study was designed to demonstrate the potential of fremanezumab in improving both migraine and depressive symptoms, compared to placebo, in patients with cumulative burden from these comorbidities.1
Discover the key insights from the UNITE study in this Head Start webinar! Listen to the short video led by Dr Giorgio Lambru as he explains the outcomes resulting in significant reductions in monthly migraine days (primary endpoint), improvements in depression scores such as HAM-D 17, and favourable tolerability—showing the potential of fremanezumab in complex cases of migraine & comorbid MDD* due to meaningful impacts on migraine, depressive symptoms and quality of life.1
*AJOVY® (fremanezumab) is not indicated for the treatment of comorbid major depressive disorder
